Specialities

Specialities

Allergic Conditions
Alopecia Areata
Atopic Dermatitis
Axial Spondyloarthritis
Immuno-oncology
COVID-19
Dermatological Conditions
Fibromyalgia
Digestive Disorders
Gout
Liver Disorders
Immunology
Paediatric Rheumatology
Neurological Disorders
Osteoarthritis
Primary Immunodeficiencies
Psoriasis
Rare Autoimmune Diseases
Respiratory Disorders
Psoriatic Arthritis
Rheumatic Diseases
Rheumatoid Arthritis
Sjögren’s Syndrome
Systemic Lupus Erythematosus
Systemic Sclerosis
Autoimmune Endocrine Disorders
Vitiligo
Vasculitis
Vaccinology
Haematological Disorders
Inflammatory Bowel Disease
Musculoskeletal Diseases
Paediatric Dermatology
Urticaria
Search

Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Artificial Intelligence in Musculoskeletal Medicine: A Scoping Review

Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

touchREVIEWS in RMD. 2024;3(2):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Axial Spondyloarthritis

Marina Magrey, ACR 2020 – Prognosis and Unmet Need in Nr-axSpA

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 30th 2020

TouchIMMUNOLOGY was delighted to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about non-radiographic axial spondyloarthritis (nr-axSpA), its prognosis and the unmet needs in its treatment.

Disclosures: Marina Magrey has served as a consultant for Novartis, Eli Lilly, Pfizer, AbbVie, UCB and Janssen. She has also performed research for Amgen and is currently doing research with AbbVie and UCB Pharmacy.

Support:  Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of virtual ACR Convergence 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face

In our late-breaking abstract coverage, we spoke with Prof. Denis Poddubnyy from Charité-Universitätsmedizin Berlin to discuss key data from EULAR 2024 on axial spondyloarthritis (axSpA). We first explored the open-label extension results of the phase 3 BE MOBILE 2 study (NCT04436640), which assessed bimekizumab's impact on 2-year radiographic progression in the spine of patients with radiographic axSpA. Hypothesized to offer superior inhibition of bone formation due to its dual action on IL-17A and IL-17B, bimekizumab's findings were compared with other treatments like ixekizumab, upadacitinib, secukinumab, and certolizumab pegol, highlighting implications for clinical practice. Additionally, we examined a recent study by Berg et al., which compared remote monitoring and patient-triggered monitoring to traditional face-to-face consultations. The discussion focuses on how these findings could influence daily practice, patient outcomes, and healthcare resource management.

Advertisement

    • Related Videos in Axial Spondyloarthritis

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup